சனோஃபி இந்தியா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

NEW DELHI: Analysts tracking primary issues believe one can subscribe to the initial public offering of Windlas Biotech, a Contract Development Manufacturing Organisation (CDMO), for the long term. The issue opens for subscription today. The Dehradun-based firm will raise Rs 165 crore through issuance of fresh equity shares, while the promoters and existing shareholders will offload 51,42,067 equity shares worth Rs 236 crore via an offer-for-sale (OFS). The price band for the issue is fixed at Rs 448-460 per share. “Windlas is focusing on formulation CDMO, and there is no peer company focusing solely on the CDMO model. Considering its return ratios and profitability, the issue seems to be fully priced. But factoring the growth drivers of the CDMO sector and opportunities available for the company, we assign a ‘subscribe for long term’ rating on the issue,” said Rajnath Yadav of Choice Broking.

Emcure pharmaRajnath yadavNirvi asharContract development manufacturing organisationWindlas biotechDehradun plantSanofi indiaCadila healthcareMarwadi sharesAngel brokingராஜ்நாத் யாதவ்நிர்வி ஆஷர்ஒப்பந்த வளர்ச்சி உற்பத்தி ஆர்கநைஸேஶந்விண்ட்லாஸ் பயோடெக்டெஹ்ராடூன் ஆலைசனோஃபி இந்தியா